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Abstract : The change in follicle-stimulating hormone (FSH) during the menopausal transition and associations 
of FSH with various diseases have been assessed by using blood samples. We examined cross-sectionally the vari-
ation of FSH levels, associations of estrone and estradiol with FSH, and associations of BMI with these hormones 
by using urinary samples from peri- and postmenopausal women in Japan. Of 4472 participants in the Urinary 
Isoflavone Concentration Survey of the Japan Nurses’ Health Study, we analyzed urinary levels of estrone, es-
tradiol and FSH in 547 women aged from 45 to 54 years. Urinary FSH levels varied widely in postmenopausal 
women and the pattern of change in urinary FSH levels seems to be similar to that in blood FSH levels in previ-
ous studies. There were no significant differences in age, body mass index (BMI), estradiol, estrone and estradiol/
estrone ratio among three groups according to the tertile of FSH. In postmenopausal women, there were signifi-
cant associations of BMI with levels of estrone and estradiol, but there was no significant association of BMI with 
FSH. Studies using urinary samples will allow us to establish a study project as a large-scale population-based 
study to determine associations between FSH and various diseases after menopause. J. Med. Invest. 66 : 297-302, 
August, 2019
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INTRODUCTION
 
Estradiol level shows a drastic decrease throughout the meno-
pausal transition and is less than the sensitivity level after 
menopause. Follicle-stimulating hormone (FSH), which is nec-
essary for follicular growth initiation and regulation of ovarian 
estrogen synthesis, increases in women during the menopausal 
transition and postmenopausal period through a feedback mech-
anism, but the level varies from low to high. Tepper et al. showed 
in a longitudinal observation study that the patterns of increase 
in FSH have three unique trajectories : high rising, medium ris-
ing and low rising (1). FSH may play important roles other than 
follicular growth initiation and regulation of ovarian estrogen 
synthesis. Recently, various studies have shown extragonadal 
effects of FSH. A higher FSH level was shown to be associated 
with an increase in frequencies of hot flashes and night sweats 
(2) and with an increase in subclinical atherosclerosis progres-
sion in women at midlife (3). On the other hand, low FSH levels 
were shown to be significantly associated with diabetes (4), 
metabolic syndrome (5) and non-alcoholic fatty liver disease in 
postmenopausal women (6). 
Although changes in estradiol and FSH and associations of 
these hormonal levels with menopausal symptoms and various 
diseases have usually been assessed by using blood samples, it 
is easier to collect urinary samples for large population-based 
studies. In epidemiological studies, the collection of urinary sam-
ples has several advantages compared with blood samples. The 
collection of urinary samples is noninvasive and can be conduct-
ed by the subjects without the health professional assistance, 
and urinary samples can be easily stored. There were several 
studies regarding estrogen and estrogen metabolites by measur-
ing urinary samples (7, 8, 9). However, there have been very few 
reports on changes in FSH determined by using urinary sam-
ples (10). In addition, it has been suggested that differences in 
race and body mass index (BMI) are involved in the differences 
in FSH trajectories (1). The variation of FSH levels in Japanese 
women may be different from that in the previous report in the 
previous report (1). The change in FSH level and the association 
of BMI with FSH during the menopausal transition and post-
menopausal period in Japanese women have not been clarified.   
We have been conducting a survey of the Japan Nurses’ 
Health Study (JNHS) since 2001 as a nationwide prospective 
cohort study, in which reproductive health-related conditions 
have been investigated in female nurses (11). A cross-sectional 
baseline survey was conducted from 2001 to 2007. As a project 
for determining the associations between FSH and various dis-
eases, we have planned to measure levels of estrogen and FSH 
by using urinary samples in peri- and postmenopausal women. 
In the present study, we examined the urinary levels of estradiol, 
estrone and FSH in women, associations of estrone and estradiol 
with FSH, and associations of BMI with these hormones. 
SUBJECTS AND METHODS
Data collection
Of 4472 participants in the Urinary Isoflavone Concentration 
Survey of the JNHS in 2015, we identified 1,752 women whose 
ages ranged from 45 to 54 years. After excluding 92 women who 
were receiving hormone therapy, we decided to use data for one 
third of the remaining women. Thus, urinary levels of estrone, 
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estradiol and FSH in 570 non-hormone users who were random-
ly selected were measured. The details of the study design for 
JNHS were shown previously (11). We asked about menopausal 
status, age at the final menstrual period (FMP), cause of meno-
pause (natural menopause, surgical menopause, menopause 
secondary to radiation therapy or chemotherapy and other ther-
apies), and past history of unilateral/bilateral oophorectomy and 
hysterectomy. Women in whom the duration from the FMP was 
less than 1 year were defined as premenopausal women, and 
women in whom the duration from the FMP was more than 1 
year were defined as postmenopausal women. The Ethics Com-
mittee of Gunma University reviewed and approved the study. 
Measurements of the concentrations of estradiol, estrone and FSH 
in urine
Participants were given urine collection kits and asked to pro-
vide early morning urine specimens immediately after waking 
up. Urine specimens were basically fasted samples. Participants 
collected urine by themselves by using the urine collection kits 
in the morning at home and mailed a urinary specimen to our 
laboratory at Gunma University. The urine aliquots were stored 
at -70℃ until using in assays. Urinary concentrations of estrone 
and estradiol were measured by a radioimmunoassay (12). It 
has been reported that urinary estradiol concentrations were 
correlated with serum estradiol concentrations, and urinary 
estrone concentrations were also correlated with serum estrone 
concentrations (12). Intra-assay and inter-assay coefficients of 
variation ranged from 7.3% to 11.5% and from 6.9% to 10.6%, 
respectively, for the estradiol assay, and they ranged from 6.5% 
to 9.7% and from 9.6% to 11.6%, respectively, for the estrone 
assay. Sensitivities in the estradiol and estrone assays were 
0.20 and 0.40 ng/ml, respectively. Urinary FSH concentrations 
were measured by a chemiluminescence immunoassay. The 
concentrations of estradiol, estrone and FSH were adjusted by 
urinary creatinine. Urinary samples (each 25 μl) were reacted 
with mouse anti-FSH monoclonal antibodies, which were im-
mobilized magnetism microparticles (50 μl). After removing 
unreacted materials, acridinium-labeled mouse anti-FSH mono-
clonal antibodies (50 μl) were added. Unreacted materials were 
removed and fluorescence intensity at 400-500 nm was mea-
sured after addition of hydrogen peroxide (300 μl). Calibrators 
were also reacted by the same methods as that used for urinary 
samples, and we obtained values of FSH based on the obtained 
standard curve. In a previous study, urinary FSH level was mea-
sured by an immunoenzymometric assay (13). The results of a 
chemiluminescence immunoassay correlate well with the results 
of an immunoenzymometric assay.
Data analysis 
Of the 570 women, 7 women who had received hysterecto-
my, one woman who had received bilateral oophorectomy, one 
woman with breast-feeding, and 22 women in whom periods 
from the FMP were unknown were excluded, and we analyzed 
data for 547 women. We compared urinary FSH concentrations 
in premenopausal women and postmenopausal women by using 
the Mann-Whitney test. We examined differences in age, years 
since menopause, BMI, urinary estrone and estradiol levels, and 
estradiol/estrone ratio between the three groups of urinary FSH 
levels by using the Kruskal-Wallis test. Spearman’s correlation 
coefficient was used to examine the correlations between estra-
diol level and estrone level, between BMI and estradiol level, be-
tween BMI and estrone level, and between BMI and FSH level. 
P < 0.05 was considered statistically significant. All statistical 
analyses were carried out using SAS ver 9.4 (SAS Institute Inc., 
Cary, NC).
RESULTS
Ages, BMIs, levels of estrone, levels of estradiol, estradiol/
estrone ratios and levels of FSH in pre- and postmenopausal 
women (< 3 years, 3-5 years and ≥ 6 years) are shown in Table 
1. Estradiol levels in postmenopausal women were extremely 
low, about 1 ng/mg creatinine. The median (25-75 percentiles) 
of estrone levels in postmenopausal women was 4.47 (3.37-6.17) 
ng/mg creatinine, which was lower than the estrone level in pre-
menopausal women. The median (25-75 percentiles) of estradiol/
estrone ratios in postmenopausal women was 0.27 (0.21-0.36), 
which was lower than that in premenopausal women. The medi-
an FSH level in postmenopausal women was significantly higher 
Table 1.　Levels of estrone, estradiol, estradiol/estrone and FSH in pre- and postmenopausal women
Premenopause
Postmenopause
< 3 years 3-5 years ≥ 6 years
Number 248 154 102 43
Age (years) 48 (46 – 50) 52 (50 – 53) 53 (51 – 54) 53 (52 – 54)
Years since
menopause (years) 1.8 (1.1 – 2.0) 4.0 (3.0 – 4.5) 8.0 (6.2 – 8.0)












































Values are indicated as medians (25-75%).
E1 : estrone, E2 : estradiol, FSH : follicle-stimulating hormone, BMI : body mass index
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than that in premenopausal women (p < 0.001). Changes in lev-
els of estradiol, estrone and FSH according to duration since the 
FMP are shown in Figure 1. In postmenopausal women, FSH 
levels varied widely from 0.2 to 172.8 mIU/mg creatinine, though 
levels of estrone and estradiol remained low in most postmeno-
pausal women. Estradiol levels showed significant positive cor-
relations with estrone levels in premenopausal women (r = 0.93, 
p < 0.01) and postmenopausal women (r = 0.67, p < 0.01). 
The correlations between estradiol and FSH and between es-
trone and FSH in postmenopausal women are shown in Figure 
2. There was no significant correlation between estrone and 
FSH (r = -0.02, p = 0.72) or between estradiol and FSH (r = -0.01, 
p = 0.92) in postmenopausal women. FSH levels varied widely 
even in postmenopausal women with low estradiol and estrone 
levels. 
We divided the postmenopausal women into three groups, a 
low FSH group, a middle FSH group and a high FSH group, ac-
cording to the tertile of FSH (Table 2). There were no significant 
differences in age, years since the FMP, BMI, estradiol level, 
estrone level and estradiol/estrone ratio among the three groups 
in postmenopausal women. 
In postmenopausal women, there were significant associ-
ations of BMI with estrone (r = 0.14, p = 0.02) and estradiol 
(r = 0.19, p < 0.01), but there was no significant association of 
BMI with FSH (r = -0.07, p = 0.21) (Figure 3). In premenopausal 
women, there was no significant association of BMI with estrone 
(r = 0.06, p = 0.38), estradiol (r = 0.02, p = 0.77) or FSH (r = -0.08, 
p = 0.24).
Figure 1.　Urinary levels of estradiol, estrone and FSH in pre- and postmenopausal women






























































r = -0.02, p = 0.72
Spearman's correlaon 
coefficient
r = -0.01, p = 0.92
Figure 2.　Correlations of urinary FSH levels with urinary levels of estradiol and estrone in postmenopausal women
Left panel : correlation of FSH with estrone, Right panel : correlation of FSH with estradiol
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DISCUSSION
In the present study, we showed that urinary FSH levels in 
Japanese postmenopausal women varied widely as was shown 
for blood FSH levels in previous studies, though estradiol levels 
were lower than the sensitivity level. There have been very few 
studies in which urinary FSH levels in postmenopausal women 
were used for research. It has been suggested that urine col-
lection might be preferable in large population-based surveys 
which study participation rates have been reduced by the 
requirement of a blood draw (7). It has been reported that mea-
surements using urinary samples were effective and efficient 
in a population-level study (10) based on the validations and 
stability of FSH measurement in urine (13). 
Randolph et al. reported that increase in FSH from 8 years 
before the FMP to 8 years after the FMP could be divided into 5 
segments : no change, a gradual increase, a marked increase, a 
slower increase and stabilization (14). Sowers et al. reported that 
FSH level had an acute increase from 2 years before the FMP to 
one year after the FMP and showed a plateau thereafter (15). In 
the present study, we showed that urinary FSH levels increased 
until about 3-5 years after the FMP and that FSH levels in 
women whose years after the FMP was more than 6 years were 
lower than those in women whose years after the FMP were 












Age (years) 52 (51 – 53) 52 (51 – 54) 53 (51 – 54) 0.27
Years since
menopause (years) 3.0 (2.0 – 5.0) 2.5 (1.4 – 4.0) 2.5 (1.7 – 4.0) 0.13
BMI 21.2 (19.6 – 23.2) 21.0 (19.6 – 24.1) 21.2 (19.2 – 22.9) 0.51
Estrone (ng/mg
creatinine) 4.55 (3.33 – 6.17) 4.31 (3.39 – 6.25) 4.47 (3.37 – 6.14) 0.72
Estradiol (ng/mg
creatinine) 1.20 (0.81 – 1.70) 1.20 (0.87 – 1.59) 1.20 (0.88 – 1.59) 0.98
E2/E1 ratio 0.27 (0.20 – 0.37) 0.27 (0.22 – 0.36) 0.27 (0.21 – 0.34) 0.78
FSH (mIU/mg
creatinine) 6.7 (3.2 – 11.2) 32.9 (25.2 – 42.5) 84.7 (66.7 – 105.0)
Values are indicated as medians (25-75%).
E1 : estrone, E2 : estradiol, FSH : follicle-stimulating hormone, BMI : body mass index
*Kruskal-Wallis test
Figure 3.　Correlations of urinary levels of estrone, estradiol and FSH with BMI in postmenopausal women
Left panel : correlation of estrone with BMI, Middle panel : correlation of estradiol with BMI



























r = -0.07, p = 0.21
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less than 6 years. The pattern of changes in urinary FSH levels 
seems to be similar with the pattern of changes in FSH levels in 
blood samples. Tepper et al. reported that the variation in FSH 
trajectories was evident after the FMP and that the FSH levels 
varied widely from about 25 to 120 mIU/ml (1). In the present 
study, urinary FSH levels also varied widely from 0.2 to 172.8 
mIU/mg creatinine. 
Estradiol secretion shifts from the ovary to a compensatory 
source in fat in postmenopausal women (16). Even if estradiol 
level is less than the sensitivity level, estrogenic activity may 
be high in women with high BMI. Obese women tend to have a 
higher estrone level, lower sex hormone-binding globulin level 
and higher free estradiol level (5). A more significant correla-
tion between estrone and BMI than that between estradiol and 
BMI has been found (17). In the present study, the proportion 
of women whose BMI was more than 25 was only 11.4% and 
there were significant associations of BMI with urinary levels 
of estrone and estradiol even in these women. However, we did 
not find a significant association between FSH level and BMI 
in postmenopausal women, although urinary FSH levels also 
varied widely. Tepper et al. reported that BMI affected the tra-
jectory of FSH changes over the menopausal transition (1). It has 
been reported that the change in FSH levels was markedly less 
pronounced in obese women than in non-obese women (14). Also, 
it has been reported that weight loss led to an increase in FSH 
level in overweight postmenopausal women (18). A possible rea-
son for the difference in the results between our study and previ-
ous studies is due to difference in BMIs in the subjects. In those 
previous studies, the proportion of women with high BMI was 
large. In the SWAN study, the proportions of women in whom 
BMI ranged from 25 to 29.9 and women in whom BMI was more 
than 30 were 25.3% and 32.1%, respectively (1). Randolph et al. 
reported that a difference in FSH levels was found in women 
with BMI between less than 30 and more than 30 (14). Estrone 
and estradiol may be very sensitive to only a small amount of 
adipose tissue in women with normal BMI, but FSH may not be 
sensitive to a small amount of adipose tissue. Another reason is 
due to the difference in the measurement between blood samples 
and urinary samples. 
In the present study, FSH levels varied from low to high and 
FSH levels according to tertile were not associated with levels of 
estrone and estradiol in postmenopausal women. Low FSH lev-
els were shown to be associated with risk of prevalent prediabe-
tes and diabetes (4), metabolic syndrome (5), non-alcoholic fatty 
liver disease (6) and 10-year atherosclerotic cardiovascular dis-
eases in postmenopausal women (19). The associations of FSH 
with these diseases may be involved in BMI. On the other hand, 
it has been reported that a higher level of FSH was associated 
with an increase in subclinical atherosclerosis progression in 
women at midlife (3), and women in high and medium FSH tra-
jectory groups had significantly larger intima-media thickness 
(20). In addition, Randolph et al. suggested that FSH levels may 
be predictive of the frequency of hot flashes in women experi-
encing vasomotor symptoms (2). A longitudinal study suggested 
that women with higher BMI have a higher risk of vasomotor 
symptoms (21). Based on the associations of high FSH with these 
diseases, the variation of FSH after menopause may be involved 
in not only BMI but also other factors. 
An increase in FSH levels may not indicate only the response 
to a decrease in estrogen in the pituitary, and FSH may have 
an independent role. There have been studies on the role of FSH 
in extragonadal tissues. At first, FSH was reported to have 
non-gonadal effects such as direct regulation of bone mass (22). 
It has also been shown that FSH receptors are expressed in the 
liver (23), adipose tissue (24) and blood vessels (25), providing 
the basis for the extrareproductive function of FSH. Recently, 
the ratio of FSH to estradiol has been used to screen for the 
occurrence of mild cognitive function in postmenopausal women 
(26). Extragonadal effects of FSH should be further examined in 
a large epidemiological study. 
We found that urinary FSH levels in postmenopausal women 
varied widely as do levels in serum FSH samples. Also, the 
changes in and the pattern of changes in urinary FSH levels 
were similar to those in serum FSH levels. Based on the results, 
it is possible to examine the associations between the occurrence 
of various diseases and urinary FSH levels. It is easier to collect 
urine samples for large population-based epidemiological stud-
ies, and results of studies using urinary samples may contribute 
to elucidation of the roles of FSH. 
A limitation of this study is the use of spot urine samples for 
hormonal measurements rather than samples of total urine out-
put over 24 hours, although morning first-void urine was used 
to obtain concentrated urine. The period of urinary collection in 
all premenopausal women could not be fixed at 1 to 10 days of 
menstruation. Since the design of the study was cross-sectional, 
investigation of longitudinal changes in urinary hormonal levels 
may be needed.
In conclusion, we showed that urinary FSH levels in Japanese 
women varied widely. Studies using urinary samples will allow 
us to establish a study project as a large population study to 
determine associations between FSH and various diseases after 
menopause.
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